[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344646-105":59,"doc-detail-344646-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","case-report-multimodal-immunotherapeutic-regimen-envafolimab-chemotherapy-radiotherapy-for-four-synchronous-primary-malignant-neoplasms-a-case-report-of-33-month-survival-and-implications-for-tumor-immunology","Case Report: Multimodal Immunotherapeutic Regimen (Envafolimab + Chemotherapy + Radiotherapy) for Four Synchronous Primary Malignant Neoplasms - A Case Report of 33-Month Survival and Implications for Tumor Immunology","","Multiple Primary Malignant Neoplasms (MPMNs) involve two or more independent malignant tumors in a single patient, either simultaneously or sequentially, creating major diagnostic and therapeutic difficulties. Immunotherapy is emerging across cancers, but its role in MPMNs remains insufficiently established. This case report describes a patient with four concurrent primary malignancies who achieved long-term survival following an envafolimab-based multimodal treatment, followed by discussion of immunotherapy mechanisms, clinical efficacy, therapeutic strategies, and ongoing challenges, aiming to inform clinical practice and future research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/case-report-multimodal-immunotherapeutic-regimen-envafolimab-chemotherapy-radiotherapy-for-four-synchronous-primary-malignant-neoplasms-a-case-report-of-33-month-survival-and-implications-for-tumor-immunology/344646/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/case-report-multimodal-immunotherapeutic-regimen-envafolimab-chemotherapy-radiotherapy-for-four-synchronous-primary-malignant-neoplasms-a-case-report-of-33-month-survival-and-implications-for-tumor-immunology/344646.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical condition does the case report focus on?","Question",{"text":112,"@type":113},"It focuses on Multiple Primary Malignant Neoplasms (MPMNs), defined as two or more independent malignant tumors in the same patient, occurring synchronously or metachronously.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatment regimen is highlighted in this report?",{"text":117,"@type":113},"The regimen is a multimodal immunotherapeutic approach combining envafolimab with chemotherapy and radiotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcome is emphasized?",{"text":121,"@type":113},"The report highlights long-term survival, described as 33-month survival, and discusses implications for tumor immunology.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344646,1790952409,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","TYPE Case Report  \nPUBLISHED 08 January 2026 DOI 10.3389/fonc.2025.1727323  \nOPEN ACCESS  \nEDITED BY  \nYee Peng Phoon,  \nCleveland Clinic, United States  \nREVIEWED BY  \nAlicia Michelle Chenoweth,  \nKing’s College London, United Kingdom Neda Dadgar,  \nAllegheny Health Network, United States  \n*CORRESPONDENCE  \nJing Zhao  \n [zzzjmail@163.com](zzzjmail@163.com)  \nRECEIVED 17 October 2025  \nREVISED 10 December 2025  \nACCEPTED 16 December 2025  \nPUBLISHED 08 January 2026  \nCITATION  \nLiu Y, Zhang Y, Zhang Y, Duan X, Gao Z, Zhang X and Zhao J (2026) Case Report:  \nMultimodal immunotherapeutic regimen (envafolimab + chemotherapy + radiotherapy) for four synchronous primary malignant neoplasms: a case report of 33-month survival and implications for tumor immunology.  \nFront. Oncol. 15:1727323 .  \ndoi: 10.3389/fonc.2025.1727323  \nCOPYRIGHT  \n© 2026 Liu, Zhang, Zhang, Duan, Gao, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCase Report: Multimodal immunotherapeutic regimen (envafolimab + chemotherapy + radiotherapy) for four synchronous primary malignant neoplasms: a case report of 33-month survival and implications for tumor immunology  \nYadong Liu 1, Yayu Zhang 1, Yu Zhang 1, Xuejuan Duan 2, Zhanjie Gao 2, Xianbo Zhang 1 and Jing Zhao 1*  \n1 Hebei General Hospital, Shijiazhuang, China, 2 Fourth Hospital of Hebei Medical University, Shijiazhuang, China  \nMultiple Primary Malignant Neoplasms (MPMNs) are deﬁned as the presence of two or more independent malignant tumors in the same patient, either simultaneously or sequentially, presenting substantial diagnostic and therapeutic challenges . In recent years, immunotherapy—an emerging therapeutic modality—has shown notable clinical efﬁcacy across a range of malignancies. This article reports a case of a patient with four concurrent primary malignancies who attained long-term survival following treatment withenvafolimab injection. Using this case as a foundation, we discuss recent advances in immunotherapy for MPMNs, covering its mechanisms of action, clinical efﬁcacy, therapeutic strategies, and current challenges. The goal is to provide a theoretical basis for clinical practice and identify future research directions.  \nKEYWORDS  \nimmunotherapy, multiple primary malignant neoplasms, treatment outcomes, clinical efﬁcacy, chemotherapy  \nIntroduction  \nMultiple Primary Malignant Neoplasms (MPMNs) are deﬁned as the synchronous or metachronous occurrence of two or more histologically distinct and mutually independent malignant tumors in a single patient. With advancements in cancer diagnosis and therapeutic technologies, patient survival has improved, contributing to the rising  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \nincidence of Multiple Primary Malignant Neoplasms (MPMNs) (1, 2) . The pathogenesis ofMPMNs remains incompletely understood but may involve genetic predisposition, environmental factors, lifestyle choices, and treatment-related factors (3) . However, thereis currently no standard treatment regimen for multiple primary malignant neoplasms (MPMNs) . Their complex biological characteristics and heterogeneity limit the efﬁcacy of conventional treatments such as surgery, chemotherapy, and radiotherapy.  \nImmunotherapy, an emerging cancer treatment approach—works by activating the patient’s immune system to target and eliminate tumors, and it has shown considerable efﬁcacy in the management of various malignancies. However, its use in MPMNsis still in the exploratory stage, and its efﬁcacy and safety warrant further investigation. Through this case","cbCairhblg1jSWub","https://ap.wps.com/l/cbCairhblg1jSWub","pdf",3334180,"English","# Introduction\n# Case presentation","[{\"question\":\"What clinical condition does the case report focus on?\",\"answer\":\"It focuses on Multiple Primary Malignant Neoplasms (MPMNs), defined as two or more independent malignant tumors in the same patient, occurring synchronously or metachronously.\"},{\"question\":\"What treatment regimen is highlighted in this report?\",\"answer\":\"The regimen is a multimodal immunotherapeutic approach combining envafolimab with chemotherapy and radiotherapy.\"},{\"question\":\"What outcome is emphasized?\",\"answer\":\"The report highlights long-term survival, described as 33-month survival, and discusses implications for tumor immunology.\"}]","Case Report: Multimodal Immunotherapeutic Regimen (Envafolimab + Chemotherapy + Radiotherapy) for Four Synchronous Primary Malignant Neoplasms - A Case Report of 33-Month Survival and Implications for Tumor Immunology | PDF",1790054754,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19239374241a8b52495277b91f15bd23.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90552638a0e7c8cb8e84085eee07f4a8.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2728e99417c4ac6f1b47c48c9b201643.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2a9d4b07586a949cb0a124009fea53b.webp",980,1385]